Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials

Magdalena Domek¹,², Jakub Gumprecht¹,³, Wern Yew Ding¹, Gregory Y. H. Lip¹,³,⁴*, and Deirdre A. Lane¹,⁴

¹Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; ²Department of Internal Diseases, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland; ³Department of Cardiology, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland; and ⁴Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The study aims to provide a comparative review of the major phase III randomized clinical trials (RCTs) and real-world data (RWD) from reliable, high-grade Phase IV studies that assess the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) vs. vitamin K antagonists (VKAs). Observational studies based on nationwide or health insurance database records on the use of NOACs vs. VKAs in patients with AF were included. We performed a comparison of the efficacy and safety characteristics associated with NOACs vs. VKAs in RCTs and RWD. Although RCTs provide strong support for evidence-based practice, RWD may be used to reflect the broader picture of various clinical settings, provide supplementary insight and fulfil knowledge gaps. Both study types confirmed the safety and efficacy of NOACs in preventing stroke and thromboembolism in patients with AF. In comparison to VKAs, NOACs were associated with reduced risk of ischaemic events and lower rates of adverse events such as major bleeding or intracranial haemorrhage. Administration of NOACs might be associated with increased risk of dose-related gastrointestinal bleeding and myocardial ischaemic events, especially in the early treatment period after switching from VKAs. Special care should be taken in challenging clinical situations like severe renal or hepatic impairment when the treatment regimen needs to be considered individually. Randomized clinical trial and RWD studies are complementary and present comparable findings, affirming that NOACs are safe and effective for anticoagulation of patients with AF in daily clinical practice.

Introduction

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia and a major cause of cerebrovascular-related mortality and morbidity.¹,² Hence, stroke prevention is an important focus in the management of AF.³ Vitamin K antagonists (VKAs, mainly warfarin), have been the treatment of choice to prevent systemic thromboembolism in AF prior to the discovery of non-vitamin K antagonist oral anticoagulants (NOACs), also known as direct oral anticoagulants.⁴,⁶ Although both groups of drugs are effective at reducing thrombo-embolic risk there is a suggestion that NOACs may be superior with regards to ease of use,
wider therapeutic range, and less major bleeding. As these drugs have been widely used for several years; there is emerging evidence regarding their safety profile from various registers.

In general, randomized control trials (RCTs) are accepted as the gold standard to assess the effectiveness and safety of therapeutic interventions. They often provide robust and high-quality evidence, from which guideline recommendations are derived. Nonetheless, the selection of patients in RCTs are based upon their strict inclusion and exclusion criteria and study setting. As a result, these trials may not be applicable to many patients with similar conditions who are encountered in daily clinical practice. In this regard, real-world data (RWD) provide a more accurate representation of the study population in the clinical setting. As a result, the popularity of real-world studies, as well as their importance in the world of science, have increased significantly over the last decade. Despite this, there are several limitations with RWD. For example, they are reliant on information from various sources such as electronic health records, patient or disease registries, and insurance databases. Therefore, the quality of data may be variable which may result in a disparity between the findings from RCTs and real-world studies. Consequently, it is important to integrate and analyse evidence from both sources, as RWD verifies and complements the data obtained from RCTs. When their findings are consistent, the reliability of the information provided increases significantly.

Since the introduction of NOACs, several research studies, either phase III clinical trials or in the real-world setting, have been conducted on their safety and therapeutic effects compared to VKAs. These studies differ considerably in terms of methodology, research group, and results.

The purpose of this study is to perform a comparative review of the data from major phase III clinical trials and real-world evidence from reliable, high-grade Phase IV studies that assess the efficacy and safety of NOACs vs. VKAs.

Methodology

We searched PubMed for observational studies based on nationwide or health insurance database records relating to the implementation of NOACs vs. VKAs in patients with AF. We conducted a comparison of efficacy and safety outcomes associated with the use of NOACs or warfarin from the following phase III, randomized trials of patients with AF: RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-TIMI 48, and RWD or Phase IV evidence with regard to the risk of stroke or systemic embolism, ischemic stroke, myocardial infarction, major haemorrhage, intracranial haemorrhage, gastrointestinal haemorrhage, and all-cause death (Table 1).

Dabigatran vs. warfarin

In light of the RE-LY study, both efficacy and safety of dabigatran were dose-dependent. Undeniably, administration of high-dose dabigatran (150 mg) compared to warfarin therapy was associated with a significant reduction in the rate of stroke or systemic embolism [relative risk (RR) 0.66, 95% confidence interval (CI) 0.53–0.82; P < 0.001], with similar overall rate of bleeding, including major haemorrhage (RR 0.93, 95% CI 0.81–1.07; P = 0.31). However, the rate of gastrointestinal bleeding with high-dose dabigatran was higher compared to warfarin therapy (RR 1.50, 95% CI 1.19–1.89; P < 0.001) (Table 1). In contrast, dabigatran at the dose of 110 mg was non-inferior compared to warfarin therapy in the rate of stroke or systemic embolism (RR 0.91, 95% CI 0.74–1.11; P = 0.34), with a significantly lower rate of bleeding, including major haemorrhage (RR 0.80, 95% CI 0.69–0.93; P = 0.003) (Table 2). Other important findings in the RE-LY study were related to a numerically but non-significant increase in myocardial infarction with high-dose dabigatran, but no statistical difference in all-cause death (Table 2).

In support of the results above, the available RWD found dabigatran to have similar efficacy compared to warfarin but with a better safety profile. Dabigatran use compared to warfarin was associated with a lower risk of intracranial haemorrhage [hazard ratio (HR) 0.42, 95% CI 0.37–0.49; P < 0.001],17–28 and all-cause death (HR 0.63, 95% CI 0.52–0.76; P < 0.001).19,20,22,25,29,30 There was no suggestion of a higher risk of myocardial infarction with dabigatran use in five studies utilizing real-world databases.18,19,25,31,32 Both RCTs and RWD were broadly consistent with comparable effects of dabigatran and warfarin in reducing the risk of stroke and systemic embolism14,31,33–36 and increased risk of gastrointestinal bleeding with high-dose dabigatran (Table 2).13,17,22,25,28

The inconsistencies observed between the RCT and RWD are likely multifactorial.

Most of the RCTs are multicentre studies which were conducted with a predominantly international western European or American population. There was often minor participation from those in other regions. Although RWD studies are also frequently performed on large populations, they usually based on nationwide cohorts, which may or may not be ethnically diverse, and might reflect the discrepancies resulting from the specific population characteristics.

Therefore, genetic and environmental factors may account for some of the differences seen. For instance, a real-world study in an Asian cohort showed no significant disparity in the risk of gastrointestinal bleeding or myocardial infarction between those on dabigatran and warfarin. Another reason for the inconsistencies may be related to inappropriate use of dosing regimens. It was previously reported that there was a frequent prescription of low-dose dabigatran among Asian patients in the real world, due to false assumptions associated with lower body size in this population.

Real-world data studies also shed light on the possibility of increased risk of gastrointestinal bleeding and myocardial infarction in patients receiving dabigatran vs. warfarin, while identifying that a switch to NOACs from VKA was associated with an initial high-risk period. This may partly be explained by the need for drug saturation and weaker attenuation of thrombin generation early on with the use of dabigatran.
| Author, year Country | Number of patients | Study design | Study groups | Findings for NOAC vs. warfarin |
|----------------------|-------------------|--------------|--------------|-------------------------------|
| Larsen, 2014 Denmark | 33 855 | Nationwide registry | Dabigatran vs. Warfarin | Highest bleeding rate in warfarin-naïve comparing to experienced users and naïve dabigatran. |
| Larsen, 2014, Denmark | 66 198 | Nationwide cohort | Patients who switched from warfarin to dabigatran vs. those who maintained on warfarin. | Switching from warfarin to dabigatran was associated with increased risk of myocardial infarction during the initial period (110 mg HR 3.01, 95% CI 1.48–6.10; 150 mg HR 2.97, 95% CI 1.31–6.73) |
| Sarrazin, 2014, USA | 85 334 | Nationwide observational study | Patients who switched from warfarin to dabigatran vs. those who maintained on warfarin | Increased risk of gastrointestinal bleeding in switchers from warfarin to dabigatran (HR 1.54, 95% CI 1.20–1.97) |
| Avgil-Tsadok, 2015, Canada | 63 110 | Population-based | Dabigatran vs. warfarin | No difference in stroke risk (HR 1.05, 95% CI 0.93–1.19) Lower rate of intracranial bleeding (HR 0.60, 95% CI 0.50–0.76) Higher rate of gastrointestinal bleeding (HR 1.30, 95% CI 1.14–1.50) |
| Bouillon, 2015 France | 17 410 | Matched cohort | Patients who switched from VKAs to NOAC vs. those who maintained on VKAs | Patients who switched from VKAs to NOACs are not associated with increased risk of bleeding compared to those who maintained VKAs. |
| Graham, 2015 USA | 134 414 | Retrospective cohort | Dabigatran vs. warfarin | Lower stroke risk (HR 0.80, 95% CI 0.67–0.96), lower intracranial bleeding risk (HR 0.34, 95% CI 0.26–0.46) and death (HR 0.86, 95% CI 0.77–0.96). Increased gastrointestinal bleeding risk (HR 1.28, 95% CI 1.14–1.44) |
| Lauffenburger, 2015 USA | 64 935 | Retrospective cohort | Dabigatran vs. warfarin | Lower risk of ischaemic stroke or systemic embolism (HR 0.86, 95% CI 0.79–0.93), haemorrhagic stroke (HR 0.51, 95% CI 0.40–0.65) and acute myocardial infarction (HR 0.94, 95% CI 0.77–0.99) and higher risk of gastrointestinal bleeding (HR 1.11, 95% CI 1.02–1.22). No significant differences between dabigatran/rivaroxaban and warfarin in bleeding or thromboembolism risk. |
| Maura, 2015 France | 32 807 | Nationwide registry | Dabigatran vs. warfarin | Rivaroxaban vs. warfarin | (continued) |
| Author, year | Country | Number of patients | Study design | Study groups | Findings for NOAC vs. warfarin |
|--------------|---------|--------------------|--------------|--------------|------------------------------|
| Seeger, 2015 | USA     | 38,378             | Nationwide registry | Dabigatran vs. warfarin | No significant difference in stroke prevention. Lower bleeding risk (HR 0.75, 95% CI 0.65–0.87). |
| Villines, 2015 | USA     | 25,586             | Retrospective cohort | Dabigatran vs. warfarin | Lower stroke (HR 0.73, 95% CI 0.55–0.97), major intracranial (HR 0.49, 95% CI 0.30–0.79), urogenital (HR 0.36, 95% CI 0.18–0.74) bleeding, MI (HR 0.65, 95% CI 0.45–0.95), and death risk (HR 0.64, 95% CI 0.55–0.74). |
| Chan, 2016    | Taiwan  | 19,853             | Nationwide registry | Dabigatran vs. warfarin | Lower stroke risk (HR 0.62, 95% CI 0.52–0.73) Lower rate of intracranial bleeding (HR 0.44, 95% CI 0.32–0.60) Lower rate of all-cause mortality (HR 0.45, 95% CI 0.38–0.53) Lower risk of ischaemic stroke and systemic embolism (HR 0.64, 95% CI 0.49–0.83; HR 0.51, 95% CI 0.35–0.74, respectively), intracranial bleeding (HR 0.44 95% CI 0.28–0.70; HR 0.30, 95% CI 0.15–0.60, respectively) and all-cause mortality (HR 0.47, 95% CI 0.33–0.67; HR 0.40, 95% CI 0.30–0.52, respectively). No difference between dabigatran and rivaroxaban. |
| Coleman, 2016 | USA     | 30,988             | Retrospective cohort | Dabigatran vs. warfarin | Lower risk of combined endpoint of ischaemic stroke or intracranial haemorrhage on rivaroxaban compared to warfarin (HR 0.61, 95% CI 0.45–0.82). Lower risk of intracranial haemorrhage on apixaban (HR 0.38, 95% CI 0.17–0.88). No difference in stroke risk. Lower annual rates of ischaemic stroke or systemic embolism (3.0% vs. 3.3%) on rivaroxaban. Lower annual risk of death on apixaban (5.2%) and dabigatran (2.7%). Lower composite outcome risk on apixaban and dabigatran (3.3% vs. 2.4% vs. 5.0%, respectively). No difference between dabigatran and rivaroxaban. |
| Larsen, 2016  | Denmark | 61,678             | Nationwide cohort | Dabigatran vs. warfarin | No difference in stroke risk. Lower annual rates of ischaemic stroke or systemic embolism (3.0% vs. 3.3%) on rivaroxaban. Lower annual risk of death on apixaban (5.2%) and dabigatran (2.7%). Lower composite outcome risk on apixaban and dabigatran (3.3% vs. 2.4% vs. 5.0%, respectively). No significant differences in bleeding, systemic embolism, and composite outcomes risk. |
| Laliberte, 2016 | Canada | 18,270             | Retrospective cohort | Dabigatran vs. warfarin | No significant difference in stroke prevention. Lower bleeding risk on apixaban (HR 0.53, 95% CI 0.39–0.71) and dabigatran (HR 0.69, 95% CI 0.50–0.96). No difference between rivaroxaban and warfarin. Higher risk of major bleeding on rivaroxaban than on apixaban (HR 1.82, 95% CI 1.36–2.43). Lower any haemorrhage risk regardless of dabigatran dose (110 mg HR 0.40, 95% CI 0.31–0.52; 150 mg HR 0.29, 95% CI 0.19–0.41). |
| Lip, 2016     | UK      | 45,361             | Retrospective cohort | Dabigatran vs. warfarin | No significant difference in stroke prevention. Lower bleeding risk on apixaban (HR 0.53, 95% CI 0.39–0.71) and dabigatran (HR 0.69, 95% CI 0.50–0.96). No difference between rivaroxaban and warfarin. Higher risk of major bleeding on rivaroxaban than on apixaban (HR 1.82, 95% CI 1.36–2.43). Lower any haemorrhage risk regardless of dabigatran dose (110 mg HR 0.40, 95% CI 0.31–0.52; 150 mg HR 0.29, 95% CI 0.19–0.41). |
| Nishtala, 2016 | New Zealand | 9,920       | International observational study | Dabigatran vs. warfarin | No significant difference in stroke prevention. Lower bleeding risk (HR 0.75, 95% CI 0.65–0.87). |

(continued)
| Author, year, Country | Number of patients | Study design | Study groups | Findings for NOAC vs. warfarin |
|----------------------|-------------------|-------------|--------------|-------------------------------|
| Yao, 2016 USA        | 152 708           | Retrospective cohort | Dabigatran vs. warfarin Rivaroxaban vs. warfarin Apixaban vs. warfarin | Lower stroke risk on apixaban (HR 0.67, 95% CI 0.46–0.98). No difference on dabigatran and rivaroxaban. Lower bleeding risk on apixaban and dabigatran (HR 0.45, 95% CI 0.34–0.59 and HR 0.79, 95% CI 0.67–0.94, respectively). |
| Bengtson, 2017 Japan  | 145 666           | Retrospective cohort | Dabigatran vs. warfarin and Rivaroxaban vs. warfarin in those switching from VKA and naïve patients | Lower stroke risk in dabigatran naïve vs. warfarin (HR 0.65, 95% CI 0.52–0.82) Similar risk in switchers from VKA to dabigatran (HR 1.20, 95% CI 0.95–1.51) No difference in stroke and bleeding risk between rivaroxaban and warfarin (HR 1.10, 95% CI 0.58–2.10, HR 0.40, 95% CI 0.05–3.59) |
| Halvorsen, 2017 Norway | 32 675         | Nationwide registry | Dabigatran vs. warfarin Rivaroxaban vs. warfarin Apixaban vs. warfarin | No difference in anticoagulant-naïve patients in stroke/systemic thromboembolism risk Lower intracranial bleeding risk on dabigatran (0.34%, 95% CI 0.47 to 0.21%) and apixaban (0.20, 95% CI 0.38 to 0.01%). |
| Staerk, 2017 Denmark  | 43 299            | Nationwide registry | Dabigatran vs. warfarin Rivaroxaban vs. warfarin Apixaban vs. warfarin | Lower risk of stroke or systemic embolism with low- or high-dose edoxaban (HR 0.57, 95% CI 0.42–0.78; HR 0.44, 95% CI 0.31–0.64, respectively) Lower rate of major bleeding with low- or high-dose edoxaban (HR 0.61, 95% CI 0.43–0.85; HR 0.40, 95% CI 0.26–0.61, respectively) Lower rate of mortality with low- or high-dose edoxaban (HR 0.55, 95% CI 0.41–0.73; HR 0.43, 95% CI 0.22–0.53, respectively) Lower risk of ischaemic stroke (HR 0.69, 95% CI 0.49–0.96), intracranial haemorrhage (HR 0.41, 95% CI 0.18–0.79), hospitalization for gastrointestinal bleeding (HR 0.60, 95% CI 0.36–0.93), hospitalization for major bleeding (HR 0.53, 95% CI 0.35–0.78), and all-cause mortality (HR 0.72, 95% CI 0.55–0.92). |
| Yu, 2018 Korea        | 11 172            | Nationwide registry | Edoxaban vs. warfarin | Lower risk of stroke or systemic embolism with low- or high-dose edoxaban (HR 0.57, 95% CI 0.42–0.78; HR 0.44, 95% CI 0.31–0.64, respectively) Lower rate of major bleeding with low- or high-dose edoxaban (HR 0.61, 95% CI 0.43–0.85; HR 0.40, 95% CI 0.26–0.61, respectively) Lower rate of mortality with low- or high-dose edoxaban (HR 0.55, 95% CI 0.41–0.73; HR 0.43, 95% CI 0.22–0.53, respectively) Lower risk of ischaemic stroke (HR 0.69, 95% CI 0.49–0.96), intracranial haemorrhage (HR 0.41, 95% CI 0.18–0.79), hospitalization for gastrointestinal bleeding (HR 0.60, 95% CI 0.36–0.93), hospitalization for major bleeding (HR 0.53, 95% CI 0.35–0.78), and all-cause mortality (HR 0.72, 95% CI 0.55–0.92). |
| Lee, 2018 Korea       | 35 765            | Nationwide registry | Edoxaban vs. warfarin | Lower risk of ischaemic stroke (HR 0.88, 95% CI 0.79–0.98) and haemorrhagic stroke (HR 0.65, 95% CI 0.46–0.92), systemic embolism (HR 0.53, 95% CI 0.43–0.65) and composite outcome (HR 0.78, 95% CI 0.71–0.86) No difference in bleeding risk. |
| Datar, 2019 USA       | 21 493            | Retrospective observational study | NOACs vs. warfarin | Lower risk of ischaemic (HR 0.88, 95% CI 0.79–0.98) and haemorrhagic stroke (HR 0.65, 95% CI 0.46–0.92), systemic embolism (HR 0.53, 95% CI 0.43–0.65) and composite outcome (HR 0.78, 95% CI 0.71–0.86) No difference in bleeding risk. |
Rivaroxaban vs. warfarin

Results from the ROCKET-AF study and RWD\textsuperscript{18,26,33,37} were comparable with regards to the influence on the risk of stroke or systemic embolism, ROCKET-AF reported a lower risk of stroke or systemic embolism with rivaroxaban compared to warfarin using an on-treatment analysis (HR 0.79, 95% CI 0.65–0.95; \( P = 0.01 \) for superiority) (Table 2). However, the risk of stroke or systemic embolism was non-significant with a conventional intention-to-treat analysis.\textsuperscript{14} Based on a systematic review and meta-analysis of 28 real-world studies, no significant difference was found between rivaroxaban and warfarin in terms of ischaemic stroke or systemic embolism risk (HR 0.73, 95% CI 0.52–1.04; \( P = 0.13 \)).\textsuperscript{13} Despite the lack of statistical difference between rivaroxaban and warfarin for the outcome of major haemorrhage\textsuperscript{21,26,29,31,33,35,37,38} either in the RCT (HR 1.04, 95% CI 0.90–1.20; \( P = 0.58 \)) or RWD (HR 1.00, 95% CI 0.92–1.08; \( P = 0.92 \)), both the RCT and RWD concur that rivaroxaban had a significant advantage over warfarin in lowering the risk of intracranial haemorrhage (RCT: HR 0.67, 95% CI 0.47–0.93; \( P = 0.02 \)).\textsuperscript{13,14,18,21,24,26,33,37,39} Both types of studies consistently found no significant difference between rivaroxaban and warfarin therapy in the risk of myocardial infarction\textsuperscript{18,31} and all-cause death\textsuperscript{29,33} (Table 2). Moreover, the use of rivaroxaban was associated with a higher risk of gastrointestinal haemorrhage compared to warfarin\textsuperscript{18,26,33,37} (Table 3).

Apixaban vs. warfarin

Most studies on apixaban were positive with a favourable risk-benefit ratio.\textsuperscript{13,24,26} Moreover, in the RWD, the analysed outcomes (stroke, all-cause mortality, major haemorrhage, intracranial, and gastrointestinal bleeding rates), were even more beneficial than in the RCT.\textsuperscript{13} In the ARISTOTLE study, compared to warfarin, apixaban significantly reduced the risk of stroke or systemic embolism (HR 0.79, 95% CI 0.66–0.95; \( P = 0.01 \)) and also decreased the risk of bleeding, including major and intracranial haemorrhage (HR 0.69, 95% CI 0.60–0.80; \( P < 0.001 \); HR 0.42, 95% CI 0.30–0.58; \( P < 0.001 \), respectively) (Table 3). There was no difference between apixaban and warfarin in the risk of gastrointestinal bleeding in the ARISTOTLE trial (HR 0.89, 95% CI 0.70–1.15; \( P = 0.37 \)), while the risk of GI bleeding was significantly lower with apixaban in the RWD (HR 0.63, 95% CI 0.42–0.95; \( P = 0.03 \)).\textsuperscript{21,29} Similar findings that were reported in the RCT for other parameters were observed in the RWD, which supports and confirms the superiority of apixaban over warfarin (Table 4).\textsuperscript{21,24,26,29,30,38,39} Another important finding in the RCT, which was consistent in real-world studies was the significant reduction in all-cause death with apixaban compared to warfarin (RCT: HR 0.89, 95% CI 0.80–0.998; \( P = 0.047 \); RWD: HR 0.65, 95% CI 0.56–0.75; \( P < 0.00001 \)).\textsuperscript{15,29} Additionally, apixaban therapy in ARISTOTLE was associated with a lower rate of discontinuation compared to warfarin (25.3% vs.
27.5%, \( P < 0.001 \), respectively). Unlike RCTs, discontinuation rates are rarely analysed in the RWD. From the limited data available, a study on 51 000 patients with AF showed no relevant differences in discontinuation rates between the use of apixaban and warfarin. However, a separate real-world study demonstrated higher adherence to apixaban compared to warfarin in the long-term.

### Edoxaban vs. warfarin

There are more real-world or Phase IV evidence on the effects of edoxaban compared to other NOACs. There are two approved edoxaban dose regimens, based on patients' individual characteristic: high-dose edoxaban regimen (60 mg) and reduced to 30 mg (low-dose edoxaban regimen) used in patients when estimated creatinine clearance...
(CrCl) of 30–50 mL/min, a body weight of 60 kg, or the concomitant use of specific PgP inhibitors.

In general, the RWD are consistent with the ENGAGE AF-TIMI 48 study, supporting the better safety profile of edoxaban compared to warfarin. In the RCT, both edoxaban treatment regimens (low- or high-dose) were non-inferior in comparison to warfarin for stroke prevention, but the study placed a greater emphasis on the higher efficiency in stroke prevention with use of the higher, recommended dose. Moreover, both doses of edoxaban were associated with reduced adverse events including major bleeding, cardiovascular death, and composite outcome (defined as stroke/systemic embolism or cardiovascular death) compared to warfarin.42 The aforementioned results were broadly consistent with those from RWD studies but also indicated the efficacy of the lower edoxaban dose in stroke prevention and systemic embolism but with a lower risk of intracranial bleeding. This was a consistent finding observed throughout all the major studies, in both the RCTs and RWD. Overall, NOACs were characterized by a favourable risk-benefit ratio due to a better safety profile compared to warfarin. An additional advantage of NOACs over warfarin based on comprehensive comparisons of real-world outcomes in patients with AF was the substantial reduction in healthcare costs.45 Moreover, expenditure for all-cause hospitalization and outpatient medical care were lower for NOACs compared with warfarin.46 In terms of practicality and patient satisfaction, a further advantage of NOACs was related to better patients adherence due to ease of use with no need for frequent laboratory monitoring or dose adjustments. Furthermore, NOACs were proven to have fewer interactions with food and other medications compared to warfarin.47

Several analyses have assessed whether the superiority of NOACs over warfarin was dependent on anticoagulation control with warfarin therapy (i.e. time-in-therapeutic range).48,49 Nonetheless, well-managed warfarin therapy was proven to be efficient and associated with low risk of adverse events,46 NOAC medication seems to have better adherence, and therefore, in general, are associated with better outcomes.49 Hence, it appears that NOACs may be a better option for patients with difficulties in maintaining adequate anticoagulation control with warfarin.50,51

### Table 4. Apixaban in comparison to VKA

| Event                          | Real-world data studies13 | ARISTOTLE trial15 |
|-------------------------------|---------------------------|-------------------|
| Dose (mg)                     | Apixaban dose adjusted    | Apixaban 5 mg     |
| Stroke or systemic embolism   | Lower rate                | Lower rate        |
|                               | (HR 0.67, 95% CI 0.46–0.98; P = 0.04) | (HR 0.79, 95% CI 0.66–0.95; P = 0.01) |
| Ischaemic stroke              | No statistical difference | Lower rate        |
|                               | (HR 0.95, 95% CI 0.75–1.19; P = 0.65) | (HR 0.92, 95% CI 0.74–1.13; P = 0.42) |
| Myocardial infarction         | Not available             | No statistical difference |
|                               |                           | (HR 0.88, 95% CI 0.66–1.17; P = 0.37) |
| Death                         | Lower rate                | Lower rate        |
|                               | (HR 0.65, 95% CI 0.56–0.75; P < 0.000001) | (HR 0.89, 95% CI 0.80–0.998; P = 0.047) |
| Major haemorrhage             | Lower rate                | Lower rate        |
|                               | (HR 0.65, 95% CI 0.56–0.75; P < 0.000001) | (HR 0.69, 95% CI 0.60–0.80; P < 0.001) |
| Intracranial haemorrhage      | Lower rate                | Lower rate        |
|                               | (HR 0.45, 95% CI 0.31–0.63; P < 0.000001) | (HR 0.42, 95% CI 0.30–0.58; P < 0.001) |
| Gastrointestinal haemorrhage  | Lower rate                | No statistical difference |
|                               | (HR 0.63, 95% CI 0.42–0.95; P = 0.03) | (HR 0.89, 95% CI 0.70–1.15; P = 0.37) |

ARISTOTLE, Apixaban for reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.

---

**Non-vitamin K antagonist oral anticoagulants as a group**

When considering the individual NOACs as a group, despite minor differences in the effects of each drug, mainly in terms of gastrointestinal haemorrhage and major bleeding, they are all as effective as warfarin in preventing stroke or systemic embolism but with a lower risk of intracranial bleeding. This was a consistent finding observed throughout all the major studies, in both the RCTs and RWD. Overall, NOACs were characterized by a favourable risk-benefit ratio due to a better safety profile compared to warfarin. An additional advantage of NOACs over warfarin based on comprehensive comparisons of real-world outcomes in patients with AF was the substantial reduction in healthcare costs.45 Moreover, expenditure for all-cause hospitalization and outpatient medical care were lower for NOACs compared with warfarin.46 In terms of practicality and patient satisfaction, a further advantage of NOACs was related to better patients adherence due to ease of use with no need for frequent laboratory monitoring or dose adjustments. Furthermore, NOACs were proven to have fewer interactions with food and other medications compared to warfarin.47

Several analyses have assessed whether the superiority of NOACs over warfarin was dependent on anticoagulation control with warfarin therapy (i.e. time-in-therapeutic range).48,49 Nonetheless, well-managed warfarin therapy was proven to be efficient and associated with low risk of adverse events,46 NOAC medication seems to have better adherence, and therefore, in general, are associated with better outcomes.49 Hence, it appears that NOACs may be a better option for patients with difficulties in maintaining adequate anticoagulation control with warfarin.50,51 Also
some of NOACs such as Apixaban appear to be safer in terms of gastrointestinal bleeding risk. Nonetheless, there are some considerations with the use of NOACs. Importantly, there is limited evidence to support their use in patients with a severe reduction in kidney function. In fact, this group of patients were systematically excluded from RCTs studying the effects of NOACs in comparison to warfarin. Therefore, the efficacy and safety profile of these drugs in patients with severe kidney impairment remains uncertain. A large meta-analysis of cohort studies showed that among patients with AF and concomitant severe kidney impairment, the use of apixaban was associated with a lower risk of major bleeding and similar risk of thromboembolism compared to warfarin. Interestingly, however, the benefits of warfarin in reducing stroke risk among these patients have not been established. Therefore, the comparable thrombo-embolic risk in those receiving apixaban and warfarin in the previous trial may be due to the lack of effectiveness of both these drugs.

Another issue is the possibility of use NOACs as an alternative to VKAs in patients with valvular heart disease and prosthetic valve replacement, namely those with biological and mechanical prosthetic valves (MPV). Mechanical prosthetic valves are considered as more thrombogenic than biological prosthetic valves (BPV), hence the standard therapeutic option is long-term anticoagulation with VKAs as NOACs are currently not recommended in patients with MPV.

In many analysis, NOACs are considered as alternatives to VKAs in patients with BPV. No significant differences were found between NOACs and VKAs in terms of primary outcomes including stroke or systemic embolism, all-cause stroke, ischaemic stroke, myocardial infarction, all-cause death, and cardiovascular death as well as its safety regarding occurrence of bleeding (major bleedeing, intracranial haemorrhage, and gastrointestinal haemorrhage). That indicates that NOACs, mainly edoxaban and apixaban are safe and effective also in patients with AF and prior BPV replacement or valve repair.

Overall, further studies are needed to understand the mechanism contributing to thrombo-embolic risk in AF and kidney impairment.

### Conclusions

Randomized controlled trials are the cornerstone for determining the safety and efficacy of novel treatments while RWD evaluates the results from the implementation of this treatment in a broader range of clinical environments. Both study types are complementary to one another and

---

### Table 5: Edoxaban in comparison to VKA

| Event                        | Real-world data studies | ENgage AF-TIMI 48 trial |
|------------------------------|-------------------------|-------------------------|
|                              | Edoxaban 60 mg          | Edoxaban 30 mg          | Edoxaban 60/30 mg |
| Stroke or systemic embolism  | Lower rate              | Lower rate              | No statistical difference |
|                              | (HR 0.44,               | (HR 0.57,               | (HR 1.13,           |
|                              | 95% CI 0.31-0.64;       | 95% CI 0.42-0.78;       | 95% CI 0.97-1.31;  |
|                              | P < 0.05                | P < 0.05                | P = 0.12           |
| Ischaemic stroke             | No statistical difference | No statistical        |
|                              | (HR 0.67,               | difference              | (HR 1.00,           |
|                              | 95% CI 0.36-1.15;       | (HR 0.73,               | 95% CI 0.83-1.19;  |
|                              | P = 0.18                | 95% CI 0.48-1.08;       | P = 0.97           |
| Myocardial infarction        | Lower rate              | Lower rate              | No statistical difference |
|                              | (HR 0.34,               | (HR 0.58,               | (HR 0.94,           |
|                              | 95% CI 0.15-0.81;       | 95% CI 0.35-0.98;       | 95% CI 0.74-1.19;  |
|                              | P < 0.05                | P < 0.05                | P = 0.60           |
| Death                        | Lower rate              | Lower rate              | No statistical difference |
|                              | (HR 0.34,               | (HR 0.55,               | (HR 0.92,           |
|                              | 95% CI 0.15-0.81;       | 95% CI 0.41-0.73;       | 95% CI 0.83-1.01;  |
|                              | P < 0.05                | P < 0.05                | P = 0.08           |
| Major haemorrhage            | Lower rate              | Lower rate              | Lower rate          |
|                              | (HR 0.40,               | (HR 0.61,               | (HR 0.80,           |
|                              | 95% CI 0.26-0.61;       | 95% CI 0.43-0.85;       | 95% CI 0.71-0.91;  |
|                              | P < 0.05                | P < 0.05                | P = 0.001          |
| Intracranial haemorrhage     | Lower rate              | Lower rate              | Lower rate          |
|                              | (HR 0.35,               | (HR 0.44,               | (HR 0.47,           |
|                              | 95% CI 0.15-0.83;       | 95% CI 0.24-0.82;       | 95% CI 0.34-0.63;  |
|                              | P < 0.05                | P < 0.05                | P = 0.001          |
| Gastrointestinal haemorrhage | Lower rate              | Lower rate              | Higher rate         |
|                              | (HR 0.42,               | (HR 0.59,               | (HR 1.23,           |
|                              | 95% CI 0.26-0.69;       | 95% CI 0.40-0.88;       | 95% CI 1.02-1.50;  |
|                              | P < 0.05                | P < 0.05                | P = 0.03           |

ENGAGE AF-TIMI 48, The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
should be used to provide a better understanding of the management of complex conditions such as AF. By comparing the RCTs and RWD on NOACs, we revealed a significant agreement between the results that demonstrate the efficacy and safety profile with this group of medications. Given the broad range of treatment options available for patients with AF, it is important that as clinicians, we are able to offer individualized treatment options.

**Funding**

J.G. was supported by the Polish Cardiac Society Club 30 Specialized Research Fellowship Grant for Early Career Researcher. This paper was published as part of a supplement financially supported by an unrestricted educational grant from Daichi Sankyo Europe GmbH.

**Conflict of interest:** none declared.

**References**

1. Go AS, Hylek EM, Phillips KA, Chang Y, Renault LE, Selby Jv, Singer DE; Authors/Task Force Members. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001;285:2370-2375.

2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Cecconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendra M, Torbicki A, Vahanian A, Wedel DE, Vardas P; Al-Attar N, Angelini A, Blomström-Lundqvist C, Colonna P, De Sutter J, Ernst S, Gorenek B, Hatala R, Heldbäck U, Heldal M, Kristensden SD, Kolh P, Le Heuzey J-Y, Mavrakis H, Mont L, Filardo PP, Ponikowski P, Prendergast B, Rutten FH, Schottelen U, Van Gelder IC, Verheugt FWA. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. *Eur Heart J* 2012;33:2719-2747.

3. Lip G. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol* 2017;14:627-628.

4. Hald EM, Rinde LB, Lachen ML, Mathiesen EW, Wilsgaard T, Njøstad I, Bækken SK, Hansen JB. Atrial fibrillation and cause-specific risks of pulmonary embolism and ischemic stroke. *J Am Heart Assoc* 2018;7:1-18.

5. Gallego P, Roldan V, Marín F, Romera M, Valdes M, Vicente V, Lip G. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol* 2017;14:627-628.

6. Camell M, Mandoli GE, Loiacono F, Spera S, Lardino E, Mondillo S. Left atrial strain: a useful index in atrial fibrillation. *Thromb Haemost* 2013;109:1189-1198.

7. Husted S, De Caterina R, Andreotti F, Arniesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz J; the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. *Thromb Haemost* 2014;111:781-782.

8. Hylek EM, Evans-Molina C, Shea C, Renault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation* 2007;115:2689-2696.

9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themes E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Alings AMW, Amerena JF, Avezum A, Baumgartner I, Brugada J, Budaj A, Caiocco V, Cereuzynsky L, Chen JH, Commerford PJ, Connolly SJ, Dans AL, Darius H, Di Pasquale G, Diaz Erol C, Ezekowitz MD, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Gamboa R, Golitsyn SP, Gonzalez Hermosillo JA, Halon D, Heldbäck U, Hohnloser SH, Hohnloser SH, Hori M, Huber K, Jansky P, Kamensky G, Keltai M, Kim S, Lau CP, Le Heuzey JYF, Lewis BS, Liu LS, Nanjas N, Oldgren J, Pias PS, Parkhomenko AN, Pedersen KE, Piegsa LS, Rae D, Razali O, Simmers TA, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139-1151.

10. Birmen-Dech E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. *Stroke* 2006;37:1070-1074.

11. Frieden TR. Evidence for health decision making-beyond randomized, controlled trials. *N Engl J Med* 2017;377:465-475.

12. Saturni S, Bellini F, Braido F, Paggioro P, Sanduzzi A, Scichilone N, Santos PA, Morandi L, Papa A. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. *Pulm Pharmacol Ther* 2014;27:129-138.

13. Harari S. Randomised controlled trials and real-life studies: two answers for one question. *Eur Respir Rev* 2018;27:180000.

14. Ntaios G, Pavasasileou V, Makartisski K, Vemmos K, Michels P, Lip G. Real-world setting comparison of non-vitamin K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. *Stroke* 2017;48:2494-2503.

15. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz FD, Kox KAII, Califf RM; the ROCKET AF Steering Committee. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883-891.

16. Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, Petroni G, Lujan S, Pinehole J, Barber J, Machamer J, Chaddock K, Celleck JM, Chernier M, Hendrix T. A trial of intracranial-pressure monitoring in traumatic brain injury. *N Engl J Med* 2012;367:2471-2481.

17. Camelli M, Mandoli GE, Loiacono F, Spera S, Lardino E, Mondillo S. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. *J Cardiof* 2017;69:886-876.

18. Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. *Stroke* 2016;47:441-449.

19. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houtson M, Macurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvar atrial fibrillation. *Circulation* 2015;131:157-164.

20. Halvorsen S, Ghanima W, Tveten I, Brækkan SK, Hansen JB. Atrial fibrillation and cause-specific risks of thrombotic events in patients with atrial fibrillation. *Thromb Haemost* 2013;110:1189-1198.

21. Husted S, De Caterina R, Andreotti F, Arniesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz J; the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. *Thromb Haemost* 2014;111:781-782.

22. Hylek EM, Evans-Molina C, Shea C, Renault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation* 2007;115:2689-2696.
dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014;127:650-656.e5.

28. Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P. Bleeding rates in veterans affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014;127:1179-1185.

29. Larsen TB, Skjæth F, Nielsen PB, Kjaergaard JN, Lip G. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagu-

30. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Calléros T, Rosenzweig M, Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Comparison of the short-term risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation patients treated with dabigatran compared with warfarin: a meta-analysis of randomised trials. Lancet 2014;383:955-962.

31. Chen YH, Kuo CT, Yeh YH, Chang SH, Wu LS, Lee HF, Hu TF, See LC. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in atrial fibrillation. Am J Cardiol 2016;118:1390-1401.

32. Launfenburger JC, Farley JF, Gehl AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc 2015;4:1-12.

33. Maura G, Blotière P-D, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients treated with dabigatran or rivaroxaban versus vitamin K antagonists A French nationwide propensity-matched cohort study. Circulation 2015;132:1252-1260.

34. Sørensen R, Gislon G, Torg-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, Karosy D, Lamberts A, Charlot M, Keber L, Weeke P, Lip GYH, Hansen ML. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013;3:e002758.

35. Laliberté F, Cloutier M, Nelson WW, Coleman Cl, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-1325.

36. Lip GYH, Keshian A, Kamble S, Pan X, Mardejan J, Horbury R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: a propensity score matched analysis. Thromb Haemost 2016;116:975-986.

37. Coleman CI, Antt Z, Bowkin K, Evers T, Simard EP, Bonnefier H, Cappetto R. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin 2016;32:2047-2053.

38. Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 2011;99:882-893.

39. Sørensen R, Jamie Nielsen B, Langvedt Pallisgaard J, Ji-Young Lee C, Mercuri M, Antman EM, Peruzzotti-Jametti L, Malynovsky Y, Morin JL, Waldo AL, Ezekowitz MD, Weitz JI, Mercuri M, Antman EM, Peruzzotti-Jametti L, Malynovsky Y, Morin JL, Waldo AL, Ezekowitz MD, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:339-351.

40. Chokesuwattanasuk R, Thongprayoon C, Tanawattitw T, Kaewput W, Pacharayon P, Cheungsapitorn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing Clin Electrophysiol 2018;41:627-634.

41. Kumar S, Lusignan S, de McGregor A, Correa A, Hritskova M, Gatenby P, Jones S, Goldsmith D, Camm AJ. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ 2018;360:k342.

42. Keskar V, McArthur E, Wald R, Harel Z, Zimmerman D, Molnar AO. Comparison of real-world outcomes in patients with atrial fibrillation on rivaroxaban or dabigatran compared with warfarin: a retrospective matched population study. Thromb Haemost 2015;114:1317-1325.

43. Lee SR, Choi EK, Han K, Do Jung JH, Oh S, Lip G. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol 2018;72:838-853.

44. Datar M, Crivera C, Rozjabeth H, Abbass IM, Xu Y, Pasquale MK, Schein JR, Andrews GA. Comparison of real-world outcomes in patients with non-valvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin. Am J Heal Pharm 2019;76:275-285.

45. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer D. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors In Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401.

46. Kirchof P, Béchier S, Kiechl S, Abela A, Attar D, Casabell M, Diener H-C, Heidbuchel H, Hendriks J, Hirdgins G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Aegawi S, Camm J, Baron Ekielswia G, Budi W, Carej R, Casselman F, Coca A, De Caterina R, Defteeres E, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenke B, Guenou M, Hohnloser SH, Kolb P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Weindecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962.

47. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJJ, Själander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol 2016;1:172.

48. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flaherty P, Franzosi MG, Pais P, Dans A, Elkelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983.

49. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41.

50. Gallagher AM, Setakis E, Plumb JM, Clemens A, Staa TP. Van Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Res 2011;126:968-977.

51. Ruff CT, Giugliano RP, Braunwald E, Hoffmann EB, Deenadayalu N, Akrami KM, Roever L, Duraes AR. Comparison of the new oral anticoagu-

52. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Akrami KM, Roever L, Duraes AR. Comparison of the new oral anticoagu-
Erratum

Erratum to: Practice-derived data on Non-vitamin K antagonist Oral Anticoagulant (NOAC) therapy to complement observations from randomized trials [European Heart Journal Supplements 2020;22:i1–i12, doi:10.1093/eurheartj/suaa100]

In the originally published version of this manuscript, several errors were noted and listed in this erratum.

Upon the original publication, there was an error under the “Edoxaban vs. warfarin” heading. The text in the first paragraph should read: “body weight of 60 kg, or the concomitant use of specific PgP inhibitors.” instead of “body weight of 60 kg, or the concomitant use of verapamil or quinidine.”.

Upon the original publication, there were two errors in Table 5, Edoxaban in comparison to VKA. The errors are as follows:

The first column heading under “ENGAGE AF-TIMI 48 trial” should read: “Edoxaban 60/30 mg” instead of “Edoxaban 60 mg”.
Table 5, included column Edoxaban 30mg” under the heading: “ENGAGE AF-TIMI 48 trial”. This has been deleted.

These have now been corrected online. The publisher apologises for the errors.

Published on behalf of the European Society of Cardiology. © The Author(s) 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com